The latest announcement is out from Monogram Orthopaedics Inc (MGRM).
Monogram Orthopaedics, Inc. has shared promising updates on its mBôs surgical system after consulting with the FDA. The feedback suggests their test plans and an international clinical trial involving 100 knee surgeries could be sufficient to demonstrate the system’s safety and efficacy, potentially expediting the 510(k) submission for clearance. The anticipated cost-saving OUS trial, estimated at $1.5M, aligns with the FDA’s supportive stance on a less burdensome approach for clinical data. This development could significantly benefit the company’s timeline and budget for bringing the product to market.
For an in-depth examination of MGRM stock, go to TipRanks’ Stock Analysis page.
